Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2026-06-02 14:04:15 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1007/s00125-025-06593-2
文献链接: https://link.springer.com/10.1007/s00125-025-06593-2
其他信息:
出版社: Springer Science and Business Media LLC
作者: Dalong Zhu; Jianhua Ma; Weimin Wang; Bimin Shi; Xiaolin Dong; Fang Bian; Qingju Li; Yihua Wang; Chengyan Jiang; Xueying Wang; Kun Wang; Hongwei Ling; Xiaoxia Shi; Zhifeng Cheng; Guoyue Yuan; Liping Li; Xiuhai Su; Yibing Lu; Weihong Song; Yawei Zhang; Wen Hu; Xin Zhang; Haifang Wang; Yu Liu; Jifang Li; Lili Zhang; Yan Liu; Xiaokun Sun; Xiaoyue Wang; Keqin Zhang; Yongcai Zhao; Lili Zhang; Tianrong Pan; Ping Li; Shu Li; Haifeng Zhou; Chengxia Jiang; Xin Zheng; Lin Ni; Bo Feng; Feng Li; Lianshan Piao; Hongwei Jin; Yang Liu; Hongyi Cao; Yufeng Li; Hanqing Cai; Hong Mao; Yongqian Liang; Jianchao Guo; Yangang Wang; Yan Li; Ning Xu; Jinan Zhang; Qiu Zhang; Wuyan Pang; Jianxin Yu; Yulong Xu; Yue Zhou; Yiming Li; Qinghua Wang
全文下载地址: https://link.springer.com/content/pdf/10.1007/s00125-025-06593-2.pdf
